OBJECTIVE: The insulin-like growth factor (IGF) pathway plays a critical role in the growth and development of the uterus and is believed to function as a mediator of steroid hormone actions in the endometrium. The local expression of genes encoding IGFs and IGF-binding proteins (IGFBPs) is important in determining IGF bioactivity in the uterus. Genetic variation in key genes within the IGF pathway may influence the rate of cellular proliferation and differentiation in the uterus and ultimately affect the risk of endometrial cancer. Our hypothesis is that variant alleles in key genes involved in the IGF pathway will influence the development of endometrial cancer. METHODS: We conducted a case-control study nested within the Nurses' Health Study (NHS) and the Women's Health Study (WHS) to investigate the association between forty-four polymorphisms within IGFI, IGFII, IGFBP-1, and IGFBP-3 with endometrial cancer risk using 692 invasive endometrial cancer cases and 1723 matched controls. We used conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) to assess the risk of endometrial cancer. RESULTS: We observed an inverse association with IGFII rs3741211 and endometrial cancer risk (OR=0.79 (95% CI: 0.63, 0.99)) and IGFII rs1004446 and endometrial cancer risk (OR=0.80 (95% CI: 0.68, 0.94)). We also observed an inverse association with IGFBP-3 rs2453839 and endometrial cancer risk (OR=0.81 (95%CI: 0.67, 0.98). However, we did not observe any statistically significant associations with the polymorphisms in IGFI and IGFBP1 and endometrial cancer risk. CONCLUSIONS: Genetic variation with IGFII and IGFBP-3 may influence endometrial cancer risk in Caucasians. Polymorphisms in IGFI and IGFBP-1 were not associated with endometrial cancer risk, but further research is needed.
OBJECTIVE: The insulin-like growth factor (IGF) pathway plays a critical role in the growth and development of the uterus and is believed to function as a mediator of steroid hormone actions in the endometrium. The local expression of genes encoding IGFs and IGF-binding proteins (IGFBPs) is important in determining IGF bioactivity in the uterus. Genetic variation in key genes within the IGF pathway may influence the rate of cellular proliferation and differentiation in the uterus and ultimately affect the risk of endometrial cancer. Our hypothesis is that variant alleles in key genes involved in the IGF pathway will influence the development of endometrial cancer. METHODS: We conducted a case-control study nested within the Nurses' Health Study (NHS) and the Women's Health Study (WHS) to investigate the association between forty-four polymorphisms within IGFI, IGFII, IGFBP-1, and IGFBP-3 with endometrial cancer risk using 692 invasive endometrial cancer cases and 1723 matched controls. We used conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) to assess the risk of endometrial cancer. RESULTS: We observed an inverse association with IGFIIrs3741211 and endometrial cancer risk (OR=0.79 (95% CI: 0.63, 0.99)) and IGFIIrs1004446 and endometrial cancer risk (OR=0.80 (95% CI: 0.68, 0.94)). We also observed an inverse association with IGFBP-3rs2453839 and endometrial cancer risk (OR=0.81 (95%CI: 0.67, 0.98). However, we did not observe any statistically significant associations with the polymorphisms in IGFI and IGFBP1 and endometrial cancer risk. CONCLUSIONS: Genetic variation with IGFII and IGFBP-3 may influence endometrial cancer risk in Caucasians. Polymorphisms in IGFI and IGFBP-1 were not associated with endometrial cancer risk, but further research is needed.
Authors: Kathryn L Terry; Shelley S Tworoger; Margaret A Gates; Daniel W Cramer; Susan E Hankinson Journal: Carcinogenesis Date: 2009-12 Impact factor: 4.944
Authors: Aimee A D'Aloisio; Jane C Schroeder; Kari E North; Charles Poole; Suzanne L West; Gregory S Travlos; Donna D Baird Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-02-24 Impact factor: 4.254
Authors: Alpa V Patel; Iona Cheng; Federico Canzian; Loïc Le Marchand; Michael J Thun; Christine D Berg; Julie Buring; Eugenia E Calle; Stephen Chanock; Francoise Clavel-Chapelon; David G Cox; Miren Dorronsoro; Laure Dossus; Christopher A Haiman; Susan E Hankinson; Brian E Henderson; Robert Hoover; David J Hunter; Rudolf Kaaks; Laurence N Kolonel; Peter Kraft; Jakob Linseisen; Eiliv Lund; Jonas Manjer; Catherine McCarty; Petra H M Peeters; Malcolm C Pike; Michael Pollak; Elio Riboli; Daniel O Stram; Anne Tjonneland; Ruth C Travis; Dimitrios Trichopoulos; Rosario Tumino; Meredith Yeager; Regina G Ziegler; Heather Spencer Feigelson Journal: PLoS One Date: 2008-07-02 Impact factor: 3.240
Authors: A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin Journal: Semin Cancer Biol Date: 2015-03-06 Impact factor: 15.707
Authors: Joseph L Usset; Rama Raghavan; Jonathan P Tyrer; Valerie McGuire; Weiva Sieh; Penelope Webb; Jenny Chang-Claude; Anja Rudolph; Hoda Anton-Culver; Andrew Berchuck; Louise Brinton; Julie M Cunningham; Anna DeFazio; Jennifer A Doherty; Robert P Edwards; Simon A Gayther; Aleksandra Gentry-Maharaj; Marc T Goodman; Estrid Høgdall; Allan Jensen; Sharon E Johnatty; Lambertus A Kiemeney; Susanne K Kjaer; Melissa C Larson; Galina Lurie; Leon Massuger; Usha Menon; Francesmary Modugno; Kirsten B Moysich; Roberta B Ness; Malcolm C Pike; Susan J Ramus; Mary Anne Rossing; Joseph Rothstein; Honglin Song; Pamela J Thompson; David J van den Berg; Robert A Vierkant; Shan Wang-Gohrke; Nicolas Wentzensen; Alice S Whittemore; Lynne R Wilkens; Anna H Wu; Hannah Yang; Celeste Leigh Pearce; Joellen M Schildkraut; Paul Pharoah; Ellen L Goode; Brooke L Fridley Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-03-14 Impact factor: 4.254